Signature Equity Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
Other funds holding JAZZ
Signature Equity Partners's JAZZ Position: Q2 2026 in Review
Signature Equity Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 19% in Q2 2026, selling an estimated $31.1K and leaving 609 shares worth $147K. The position accounts for 0.07% of the portfolio, ranked #235.
Signature Equity Partners first reported a position in JAZZ in Q4 2025 and has held it in 3 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Signature Equity Partners held 609 shares of Jazz Pharmaceuticals worth $147K as of Q2 2026.
- Signature Equity Partners sold 142 Jazz Pharmaceuticals shares in Q2 2026, an estimated $31.1K.
- Jazz Pharmaceuticals made up 0.07% of Signature Equity Partners's portfolio in Q2 2026, its #235 holding.
- Signature Equity Partners first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.